Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1611—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4415—Pyridoxine, i.e. Vitamin B6
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K31/51—Thiamines, e.g. vitamin B1
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7135—Compounds containing heavy metals
  • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

• the present invention relates to a solid pharmaceutical preparation comprising a-lipoic acid, dicalcium phosphate and a binder.
• the solid pharmaceutical preparation has an improved stability and bioavailability.
• the present invention relates to the use of and/or a method of use of the solid pharmaceutical preparation as disclosed herein for improvement of glucose transport and metabolism and/or protecting a body against free radical damages and/or oxidative stress.
• the present invention relates to treatment of and/or a method of treatment of diabetic neuropathy.
• Lipoic acid also known as a-lipoic acid, alpha lipoic acid (ALA) and as thioctic acid
• LA is a naturally occurring compound that is synthesized in small amounts by plants and animals, including humans.
• Endogenously synthesized lipoic acid is covalently bound to specific proteins, which function as cofactors for several important mitochondrial enzyme complexes such as, for example, those of pyruvate dehydrogenase, a-ketoglutarate dehydrogenase and of the branched-chain amino acids.
• proteins which function as cofactors for several important mitochondrial enzyme complexes such as, for example, those of pyruvate dehydrogenase, a-ketoglutarate dehydrogenase and of the branched-chain amino acids.
• thiol (sulfur) groups which may be oxidized
• DHLA dihydro a-lipoic acid
• LA oxidized form
• Lipoic acid is a powerful antioxidant, a critical co-factor in ATP production, regulates lipid and carbohydrate metabolism.
• Lipoic acid (oxidized form) and dihydrolipoic acid (DHLA) (reduced form) are able to regenerate antioxidants including glutathione, ascorbic acid, and a- tocopherol (indirectly).
• Both LA acid and DHLA also protect the integrity of cell membranes by interacting with antioxidants-GSH, and vitamins E and C.
• Lipoic acid is found useful in the treatment of Diabetes II; it improves glucose transport and metabolism, diabetic neuropathy, cataracts, heavy metal poisoning, burning mouth syndrome, neurodegenerative disorders like Alzheimer’s and Parkinson's disease. It also protects body against free radical damage and oxidative stress.
• Lipoic acid occurs in different forms two enantiomers (R)-(+)-lipoic acid and (S)-(-)- lipoic acid.
• (R)-(+)-lipoic acid is the pure form found in nature from the simplest organisms up to the humans. Life does not exist without it, and it is found in every cell of the body. Lipoic acid consists of 50:50 racemic mixture of the R and S enantiomers and is the commonly commercially available form of lipoic acid.
• Lipoic acid (oxidized) is labile to chemical degradation and gets converted into dihydrolipoic acid (DHLA), generating characteristic garlic like smell in formulation.
• DHLA dihydrolipoic acid
• Lipoic acid suffers from certain disadvantages, when it comes to developing a solid pharmaceutical dosage form such as tablets. In particular, it is very unstable to heat and light and is hygroscopic in nature. It has a low melting point of 60-61 °C; the natural form R-lipoic acid is unstable above 40°C. Lipoic acid undergoes a homolytic cleavage and is prone to form sticky gummy undesirable polymers, which causes problems in the manufacture of solid pharmaceutical dosage forms as well as in its release from such pharmaceutical dosage forms.
• lipoic acid can polymerize due to the heat generated during compression leading to capping problem in tablets, and partially polymerized product can cause significant stability problems for the dosage form. Further, the polymerization reduces dissolution, GI absorption and lowers the bioavailability of lipoic acid, since it is so poorly absorbed from the GI tract.
• IN 1334MUM2010 proposes to tackle these problems by adding a combination of surfactant and antioxidant.
• Preferred surfactants used in IN 1334MUM2010 are a : b : a triblock co-polymers of ethylene oxide : propylene oxide : ethylene oxide such as Lutrol FI 27, antioxidants encompass for example, chelators, antioxidative vitamins, sulfites and others.
• Lutrol F127 is present versus lipoic acid in a weight ratio of 1 to 3.
• Such high amounts of surfactants are undesirable from the toxicological point of view, especially as lipoic acid is applied in dosages of up to 1000 mg.
• the present invention relates to a solid pharmaceutical preparation comprising lipoic acid as active agent, and a stabilizer comprising dicalcium phosphate and a binder.
• the present invention further relates to a solid pharmaceutical preparation comprising lipoic acid as active agent in a safe and effective amount for improvement of glucose transport and metabolism and/or protecting a body against free radical damage and/or oxidative stress, together with a stabilizer comprising dicalcium phosphate and a binder.
• the present invention further relates to a solid pharmaceutical preparation comprising lipoic acid as active agent in a safe and effective amount for treatment of Diabetes II, diabetic neuropathy, cataracts, heavy metal poisoning, burning mouth syndrome, neurodegenerative disorders, Alzheimer’s and Parkinson's disease, together with a stabilizer comprising dicalcium phosphate and a binder; in a preferred embodiment the present invention relates to said solid pharmaceutical preparation for treatment of diabetic neuropathy.
• the present invention further relates to a method for preparing the solid pharmaceutical preparation comprising lipoic acid as active agent, and a stabilizer comprising dicalcium phosphate and a binder, wherein the preparation is a granulate.
• the method comprises dry- or wet-granulation.
• the present invention further relates to a pharmaceutical preparation
• a pharmaceutical preparation comprising ( ⁇ ) lipoic acid as active agent; a stabilizer comprising dicalcium phosphate and a vinylpyrrolidone-vinyl acetate copolymer, wherein the weight ratio from lipoic acid to dicalcium phosphate is about 2 : 1 and the weight ratio from lipoic acid to the binder is about 1 : 0.05; vitamin Bl, vitamin B6 and vitamin B12, wherein the vitamin Bl, vitamin B6 and vitamin B12 are present in relation to each other in a weight ratio of 2 : 1 : 2; and a pharmaceutically acceptable excipient comprising from 40 to 45% of a filler, and from 1 to 5% (w/w) of each of a disintegrant, of a glidant and of a lubricant.
• the present invention further relates to a method of treatment of Diabetes II, diabetic neuropathy, cataracts, heavy metal poisoning, burning mouth syndrome, neurodegenerative disorders, Alzheimer’s and/or Parkinson's disease, by administering to an individual in need of this treatment a safe and effective amount of lipoic acid together with a stabilizer comprising dicalcium phosphate and a binder.
• the present invention relates to a method of treatment of diabetic neuropathy by administering to an individual in need of this treatment a safe and effective amount of lipoic acid together with a stabilizer comprising dicalcium phosphate and a binder.
• the present invention further relates to a method of improving glucose transport and metabolism and/or protecting a body against free radical damage and/or oxidative stress, by administering to an individual in need of this improvement and/or protection a safe and effective amount of lipoic acid together with a stabilizer comprising dicalcium phosphate and a binder.
• the present invention further relates to a kit comprising the solid preparation as disclosed herein comprising lipoic acid in a safe and effective amount as active agent, and a stabilizer comprising dicalcium phosphate and a binder together with instructions to use.
• w/w and“weight as used herein means percentage by weight and generally all percentages and ratios used herein after are by weight of total preparation unless otherwise indicated.
• “about” refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated.
• the term “about” generally refers to a range of numerical values (e.g., +/- 1-3% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term “about” may include numerical values that are rounded to the nearest significant figure.
• the word "or" when used as a connector of two or more elements is meant to include the elements individually and in combination; for example, X or Y, means X or Y or both.
• the word“comprise,” and its variants, are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the materials, preparations, kits, and methods of this invention. This term encompasses the terms“consisting of’ and“consisting essentially of’.
• the word“include,” and its variants, are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the materials, preparations, kits, and methods of this invention.
• the words "preferred”, “preferably” and variants refer to embodiments of the invention that afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful and it is not intended to exclude other embodiments from the scope of the invention.
• Active “Active”,“active agent” and“active ingredients” useful herein may be categorized or described herein by their therapeutic benefit or their postulated mode of action or function. However, it is to be understood that the actives and other ingredients useful herein can, in some instances, provide more than one therapeutic benefit or function or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit an ingredient to the particularly stated function(s) or activities listed.
• safe and effective amount as used herein is meant an amount of a component, high enough to significantly (positively) modify the condition to be treated or to affect the desired result, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
• the safe and effective amount of a component will vary with the condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment, the nature of concurrent therapy, the specific form employed, and the particular vehicle from which the component is applied.
• administer refers to any method which, in sound medical practice, delivers the preparation to a subject in such a manner as to provide a therapeutic effect.
• “medication” refers to medications, such as pharmaceuticals, including prescription medications, over-the-counter medications, behind-the-counter medications and combinations thereof.
• a medication can be a supplement.
• a solid pharmaceutical preparation which meets these requirements and has an improved storage stability can be provided if it comprises besides lipoic acid as active agent a stabilizer comprising dicalcium phosphate and a binder.
• the active agent lipoic acid herein also abbreviated as ALA
• lipoic acid is present as racemic mixture.
• one embodiment of the present invention is also directed to a solid pharmaceutical preparation, wherein lipoic acid is racemic ( ⁇ ) -lipoic acid.
• the stabilizer comprises dicalcium phosphate and a binder.
• Dicalcium phosphate can be present as dihydrate (CaHPCL ⁇ 2 H2O), hemihydrate (CaHPCL ⁇ H2O) or in anhydrous form (CaHPCL).
• dicalcium phosphate is present in its anhydrous form. Therefore, one embodiment of the present invention is further directed to a solid pharmaceutical preparation, wherein the dicalcium phosphate is anhydrous dicalcium phosphate.
• dicalcium phosphate (relative to ALA) is sufficient to provide a solid pharmaceutical preparation that is stable and has a good dissolution even after long storage times. Beside a binder, no further excipient is needed to improve said stability and good dissolution even after long storage times.
• lipoic acid and dicalcium phosphate are present in relation to each other in a weight ratio from about 1 : 1 to about 10 : 1, preferably from about 1.5 : 1 to about 7 : 1, more preferably from about 1.5 : 1 to about 3 : 1, and most preferably in a weight ratio from 1.6 : 1 to 2 : 1.
• one embodiment of the present invention is further directed to a solid pharmaceutical preparation, wherein lipoic acid and dicalcium phosphate are present in relation to each other in a weight ratio from about 1 : 1 to about 10 : 1, preferably from about 1.5 : 1 to about 7 : 1, more preferably from about 1.5 : 1 to about 3 : 1, and most preferably in a weight ratio from 1.6 : 1 to 2 : 1.
• a binder is present as an adjuvant for the production of solid pharmaceutical preparation as disclosed herein to provide cohesion of the solid pharmaceutical preparation.
• Appropriate binders which can be employed in the present invention are, for example, one or more of polyvinylpyrrolidone, polyvinyl acetate, a vinylpyrrolidone- vinyl acetate copolymer, a starch paste, such as maize starch paste, a cellulose derivative, such as hydroxypropyl methylcellulose or hydroxypropyl cellulose.
• one embodiment of the present invention is as well directed to a solid pharmaceutical preparation, wherein the binder is one or more of polyvinylpyrrolidone, polyvinyl acetate, a vinylpyrrolidone- vinyl acetate copolymer, a starch paste, such as maize starch paste, a cellulose derivative, such as hydroxypropyl methylcellulose or hydroxypropyl cellulose.
• the binder is one or more of polyvinylpyrrolidone, polyvinyl acetate, a vinylpyrrolidone- vinyl acetate copolymer, a starch paste, such as maize starch paste, a cellulose derivative, such as hydroxypropyl methylcellulose or hydroxypropyl cellulose.
• the binder present in the solid pharmaceutical preparation as disclosed herein is polyvinylpyrrolidone, polyvinyl acetate, a vinylpyrrolidone-vinyl acetate copolymer and/or hydroxypropyl cellulose.
• the binder present in the solid pharmaceutical preparation as disclosed herein is a vinylpyrrolidone-vinyl acetate copolymer or a combination of a vinylpyrrolidone-vinyl acetate copolymer and hydroxypropyl cellulose.
• one embodiment of the present invention is also directed to a solid pharmaceutical preparation, wherein the binder is a vinylpyrrolidone-vinyl acetate copolymer or a combination of a vinylpyrrolidone-vinyl acetate copolymer and hydroxypropyl cellulose.
• the binder is a vinylpyrrolidone-vinyl acetate copolymer or a combination of a vinylpyrrolidone-vinyl acetate copolymer and hydroxypropyl cellulose.
• hydroxypropyl cellulose refers to a hydroxypropyl cellulose, wherein the content of hydroxypropyl group in the hydroxypropyl cellulose (hereinafter, also abbreviated to "the content of HPC group”) is from 20 to 90 weight %, preferably from 40 to 85 weight %, more preferably from 53.4 to 80.5 weight %.
• the content of a hydroxypropyl group can be determined by a method described in a section of hydroxypropyl cellulose" in the European Pharmacopoeia (Ph. Eur. 9.0).
• vinylpyrrolidone-vinyl acetate copolymer refers to a water soluble polymer made from the copolymerization of vinylpyrrolidone with vinyl acetate.
• Vinylpyrrolidone-vinyl acetate copolymer is referenced in European and US pharmacopeia (Ph. Eur. and USP) as Copovidone.
• lipoic acid and the binder are present in relation to each other in a weight ratio from about 1 : 0.1 to about 1 : 0.01, preferably in a weight ratio from about 1 : 0.1 to about 1 : 0.02, more preferably in a weight ratio from about 1 : 0.08 to about 1 : 0.03, and most preferably in a weight ratio from about 1 : 0.05.
• one embodiment of the present invention is further directed to a solid pharmaceutical preparation, wherein lipoic acid and the binder are present in relation to each other in a weight ratio from about 1 : 0.1 to about 1 : 0.01, preferably from about 1 : 0.11 to about 1 : 0.02, more preferably from about 1 : 0.08 to about 1 : 0.03, and most preferably in a weight ratio from about 1 : 0.05.
• the stability and storage properties of the present solid preparation as disclosed herein are achieved by the combination of dicalcium phosphate and the binder.
• dicalcium phosphate and the binder are present in relation to each other in a weight ratio from about 2 : 1 to about 1 : 0.01, preferably in a weight ratio from about 1 : 1 to about 1 : 0.05, more preferably in a weight ratio from about 1 : 0.5 to about 1 : 0.07, and most preferably in a weight ratio from about 1 : 0.1.
• one embodiment of the present invention is further directed to a solid pharmaceutical preparation, wherein dicalcium phosphate and the binder are present in relation to each other in a weight ratio from about 2 : 1 to about 1 : 0.01, preferably from about 1 : 1 to about 1 : 0.05, more preferably from about 1 : 0.0 to about 1 : 0.07, and most preferably in a weight ratio from about 1 : 0.1.
• the solid pharmaceutical preparation as disclosed herein can be in granule, pellet, capsule or tablet form. While capsules, tablets and suppositories provide the amount of active compound intended to be taken in each case as a clearly defined individual dose, the amount of active compound required in each case can be adapted in a simple manner by means of pellets and granules. In a preferred embodiment the solid pharmaceutical preparation as disclosed herein is in tablet form.
• Suppositories are solid, single-dose preparation prepared by compression or moulding or any other technique well known from the skilled artisan, that contains one or more active substances dispersed or dissolved in a suitable basis which may be soluble or dispersible in water or may melt at body temperature, and optionally excipients.
• Granules are flowable granular aggregates of powders which can be prepared by granulation.
• Pellets are solid, small, spherical medicament forms, such as, for example, granule grains or microtablets, having a very narrow particle-size range.
• Pellets can be produced by granulation and subsequent rounding-off (spheronisation), for example by means of plate granulation, or alternatively by pressing powders or granules to give microtablets.
• Granules and pellets represent an independent medicament form, but can also serve as intermediate product for the production of tablets. If it is intended that predetermined amounts of active compound can be administered by means of granules or pellets, these are, in order to ensure adequate dosage accuracy, also provided as portioned granules or introduced into capsules.
• the solid pharmaceutical preparation according to the invention is preferably in granule, pellet, capsule, suppository or tablet form, particular preferably in capsule or tablet form, very particular preferably in tablet form. Therefore, a further embodiment of the present invention is directed to a solid pharmaceutical preparation, which is in granule, pellet, capsule, suppository or tablet form, particular preferably in capsule or tablet form.
• a very particularly preferred embodiment of the present invention is directed to a solid pharmaceutical preparation as disclosed herein, which is a tablet.
• the solid pharmaceutical preparation is a tablet further optionally comprising one or more pharmaceutically acceptable excipient selected from the group consisting of a filler, a disintegrant, a glidant and a lubricant.
• filler is an agent increasing the bulk of the pharmaceutical preparation by providing the quantity of material which is needed to form such pharmaceutical preparation.
• a filler also serves to create desired flow properties and compression characteristics in the preparation of tablets and capsule fillers.
• Fillers usable in the present invention may be a sugar alcohol such as sorbitol or mannitol, dulcitol, xylitol or ribitol, preferably sorbitol or mannitol, particular preferably mannitol, a sugar such as glucose, fructose, mannose, lactose, saccharose or maltose, preferably lactose, saccharose or maltose, particular preferably lactose, a starch such as potato starch, rice starch, maize starch or pregelatinized starch, preferably maize starch or pregelatinized starch, particular preferably maize starch, a cellulose such as powdered cellulose or microcrystalline cellulose, preferably microcrystalline cellulose, or a
• the pharmaceutical preparation comprises microcrystalline cellulose as filler.
• Fillers are present in the pharmaceutical preparation according to one embodiment of the invention in a proportion of 0 to about 55% (w/w), preferably from about 20% to about 50% (w/w), particularly preferably from about 30% to 48% (w/w), more preferably from about 40% to about 45% (w/w).
• disintegrant refers to a compound that expands and dissolves when wet, to cause disintegration of tablets or granulates to break apart and release the active pharmaceutical agent.
• the disintegrant also functions to ensure that the compounds are in contact with the solvent, such as water.
• Disintegrants serve to disintegrate tablets or granules etc. and thus enhance dissolution of the solid dosage form upon contact with the liquid dissolution medium.
• Suitable disintegrants include crospovidone (cross linked polyvinyl N- pyrrolidone), low-substituted hydroxypropyl cellulose, carboxymethylcellulose and salts and derivatives thereof, such as crosslinked derivatives, for instance croscarmellose sodium (cross- linked polymer of carboxymethylcellulose sodium,) sodium carboxymethyl glycolate, sodium starch glycolate, carrageenan, agar, and pectin. Crospovidone, low-substituted hydroxypropyl cellulose and croscarmellose sodium are particularly preferred.
• Disintegrants are present in the pharmaceutical preparation according to the invention in a proportion of 0 to about 20% (w/w), preferably from about 0.1% to about 15% (w/w), particularly preferably from about 0.5% to about 10% (w/w), most preferably from about 1% to about 5% (w/w).
• low-substituted hydroxypropyl cellulose refers to a low- substituted hydroxypropyl cellulose wherein the content of hydroxypropyl group in the hydroxypropyl cellulose (hereinafter, also abbreviated to "the content of HPC group”) is about 5.0 to 9.9 weight %.
• the content of a hydroxypropyl group can be determined by a method described in a section of "low-substituted hydroxypropyl cellulose" in the European Pharmacopoeia (Ph. Eur. 9.0).
• Low-substituted hydroxypropyl cellulose are, for example, LH- 22, LH-32, which have a content of HPC group of about 5.0 to 7.0 weight %, or LH-23, LH-33, which have a content of HPC group of about 7.0 to 9.9 weight %.
• lubricant refers to an inactive ingredient used to prevent sticking of ingredients to one another in capsule filling or tablet compressing machines.
• a lubricant reduces the sliding friction of the tableting material and ram in the mould during the tableting operation and to prevent sticking to the rams.
• Suitable lubricants are alkaline-earth metal salts of fatty acids, such as magnesium stearate or calcium stearate, fatty acids, such as stearic acid, higher fatty alcohols such as cetyl alcohol or stearyl alcohol, fats such as glyceryl dipalmitostearate, glyceryl distearate, stearin or glyceryl dibehenate, alkaline-earth metal salts of C16-C18 alkyl substituted dicarbonic acids such as sodium stearyl fumarate, hydrated vegetable oils such as hydrated castor oil or hydrated cotton seed oil, or minerals such as talc.
• fatty acids such as magnesium stearate or calcium stearate
• fatty acids such as stearic acid
• higher fatty alcohols such as cetyl alcohol or stearyl alcohol
• fats such as glyceryl dipalmitostearate, glyceryl distearate, stearin or glyceryl
• Lubricants are magnesium stearate, stearic acid or sodium stearyl fumarate as lubricant, particular preferred is magnesium stearate.
• Lubricants are present in the pharmaceutical preparation according to the invention in a proportion of 0 to about 5% (w/w), preferably about 0.1% to about 3% (w/w), particularly preferably about 0.5% to about 2.5% (w/w), most preferably about 2.0% (w/w).
• glidant refers to an inactive ingredient used as a flow aid that improves the flow characteristics of particulates such as powders or granules.
• flow characteristics of the composite or the mixtures containing the composite during further processing such as encapsulation or tableting.
• Nonlimiting examples of glidants for use in the present invention include colloidal silicon dioxide (Aerosil 200, Cab-O-Sil), talc, magnesium carbonate, and combinations thereof.
• Glidants are present in the pharmaceutical preparation according to the invention in a proportion of 0 to about 7.5% (w/w), preferably about 0.1% to about 5% (w/w), particularly preferably about 0.5% to about 4% (w/w), most preferably about 3% (w/w).
• the solid pharmaceutical preparation is a tablet comprising 25 to 100 % (w/w), preferably 30 to 80% (w/w), more preferably 35 to 70% (w/w) of the pharmaceutically acceptable excipient comprising 0 to 55 % (w/w) of a filler, 0 to 20 % (w/w) of disintegrant, 0 to 5 % (w/w) of a lubricant 0 to 7.5 % (w/w) of glidant, based upon the total weight of the tablet, preferably the pharmaceutically acceptable excipient further comprises a total of 0 to 20 % (w/w), preferably 0.1 to 20 % (w/w) of one or more additional pharmaceutically acceptable excipients, based upon the total weight of the tablet.
• the solid pharmaceutical preparation may comprise, besides lipoic acid, one or more further active ingredients such as vitamins, preferably water-soluble vitamins, more preferably B vitamins, most preferably vitamin Bl, vitamin B6 and/or vitamin B12. Therefore, the present invention is also directed to a solid pharmaceutical preparation, further comprising one or more vitamins, preferably one or more water-soluble vitamins, more preferably one or more B vitamins, most preferably vitamin Bl, vitamin B6 and/or vitamin B12. Presence of B vitamins is of particular value if the preparation is intended to be used for the prophylaxis or treatment of neural disorders such as diabetic peripheral neuropathy.
• the lipoic acid and the one or more vitamins are present in relation to each other in a weight ratio from about 1 : 0.01 to about 1 : 1, preferably in a weight ratio from about 1 : 0.1 to about 1 : 0.5, more preferably in a weight ratio from about 1 : 0.2 to about 1 : 0.3.
• one embodiment of the present invention is further directed to a solid pharmaceutical preparation, wherein the lipoic acid and the one or more vitamins are present in relation to each other in a weight ratio from about 1 : 0.01 to about 1 : 1, preferably from about 1 : 0.1 to about 1 : 0.5, more preferably from about 1 : 0.2 to about 1 : 0.3.
• the solid pharmaceutical preparation is a granulate it can be prepared by dry- granulation or wet-granulation, preferably wet-granulation.
• one embodiment of the invention is also directed to a method for preparing a solid pharmaceutical preparation, which is a granulate, the method comprising dry-granulation or wet-granulation, preferably wet- granulation.
• Granulation refers to a process of forming granules through blending and intimate mixing of drug substances and pharmaceutical additives and an input of energy.
• the term“wet- granulation” refers to a process of forming granules from a blend of active ingredients and pharmaceutically acceptable excipients with the help of water or solvents.
• the term “dry- granulation” refers to a process of forming granules from active ingredients and pharmaceutically acceptable excipients with the help of pressure.
• a granulation liquid which preferably comprises a binder
• a powder mixture comprising the active compound together with an excipient and any further suitable adjuvants
• the mixture is converted into aggregates of suitable size (granules) and subsequently dried.
• the active compound can also be introduced into the granules by suspension in the granulation liquid.
• the conversion of the powder mixture into aggregates of suitable size can be carried out, for example, by so-called build-up granulation, for example in coating pans, by means of plate granulation or in fluidised-bed processor, for example by the Glatt or Wurster method, or by so-called reduction granulation, in which the powder mixture is firstly wetted and converted into a plastically mouldable mass and subsequently converted into aggregates of the desired size, for example by extrusion through a screen having meshes of suitable size.
• the powder mixture is pressed, for example, by means of compaction between two counter-rotating compaction rolls to give flakes, which are subse quently milled to give granules, e.g. by crushing, grinding or cutting into dry granulated particles, the granulate.
• the granulate may be further processed. Crushing, grinding, or cutting processes involve an operation that reduces the size of the compressed material such as accomplished by milling or by other operations known to those skilled in the art.
• the method for preparing the granulate comprises the steps (a) dissolving the binder, and optionally one or more pharmaceutically acceptable excipient in a solvent; (b) spraying the solution obtained by step (a) onto the lipoic acid and dicalcium phosphate in a fluidized bed granulation and drying to form granules; and (c) collecting the granules obtained by step (b).
• the present invention is also directed to a method for preparing the granulate, the method comprising the steps: (a) dissolving the binder, and optionally one or more pharmaceutically acceptable excipient in a solvent; (b) spraying the solution obtained by step (a) onto the lipoic acid and dicalcium phosphate in a fluidized bed granulation and drying to form granules; and (c) collecting the granules obtained by step (b).
• the method for preparing the granulate comprises the steps (a) mixing the binder, dicalcium phosphate and lipoic acid; (b) spraying a solvent onto the mixture obtained in step a in a fluidized bed granulation and drying to form granules; and (c) collecting the granules obtained by step (b).
• the present invention is also directed to a method for preparing the granulate, the method comprising the steps: (a) mixing the binder, dicalcium phosphate and lipoic acid; (b) spraying a solvent onto the mixture obtained in step a in a fluidized bed granulation and drying to form granules; and (c) collecting the granules obtained by step (b).
• the present invention refers to the method for preparing the pharmaceutical preparation, which is a tablet, the method comprising the steps: (a) mixing the granules obtained by the method steps as disclosed above with a disintegrant and optionally a lubricant and/or one or more further excipient; (b) compressing the mixture obtained by step (a) to give tablets; and (c) optionally film coating of the tablets prepared by step (b).
• the present invention is also directed to a method for preparing the pharmaceutical preparation, which is a tablet, the method comprising the steps: (a) mixing the granules obtained by the method as disclosed above with a disintegrant and optionally a lubricant and/or one or more further excipient; (b) compressing the mixture obtained by step (a) to give tablets; and (c) optionally film coating of the tablets prepared by step (b).
• Lipoic acid and the stable solid pharmaceutical preparation as disclosed herein can be used to any physiological and medical treatment and indication lipoic acid is known for.
• the Lipoic acid and the stable solid pharmaceutical preparation as disclosed herein are used for improvement of glucose transport and metabolism, which may be in particular helpful in treatment of Diabetes II, in particular diabetic neuropathy.
• lipoic acid and the stable solid pharmaceutical preparation as disclosed herein are intended to be used for protecting a body against free radical damage and/or oxidative stress.
• Other suitable medical use may be for heavy metal poisoning, burning mouth syndrome, neurodegenerative disorders, Alzheimer A or Parkinson's disease.
• the pharmaceutical preparation as disclosed herein may be administered internally, in particular orally.
• Dosage forms that can be orally administered such as tablets, may be swallowed immediately, slowly dissolved in the mouth, or chewed.
• Internal application requires application of the pharmaceutic composition in a dose to achieve and effect, wherein the effect remains for a sufficient period of time.
• dose as used herein is meant a volume of medication, containing an amount of a drug active suitable for administration on a single occasion, according to sound medical practice. A dose can be orally administered.
• a dose can be half of a tablet or capsule, in another example one tablet or capsule, in another embodiment 1.5 tablets or capsules, in another embodiment 2 tablets or capsules, in another embodiment 2.5 tablets or capsules, and in another embodiment 3 tablets or capsules.
• the concentration of active ingredients can be adjusted to provide the proper doses of actives given the dose size.
• a dose of solid medication may be about 600mg per day.
• a dose may be from 600mg to 1800mg per day.
• the dose is intended to be administered once a day.
• the present invention relates further to a kit comprising the solid pharmaceutical preparation as disclosed herein comprising at least lipoic acid in a safe and effective amount and a stabilizer comprising dicalcium phosphate and a binder as well as instructions to use.
• the using instruction will describe some example application scenarios as described herein, but the optimal amount, duration and frequency of application will depend on the desired effect, the severity of any condition being treated, the health and age of the user and like considerations.
• Dissolution of the solid composition comprising lipoic acid are tested by high-performance liquid chromatography with UV detection using a stability indicating method.
• Dissolution is a good test to monitor the stability of ALA as polymerized form of ALA has poor solubility in purified water.
• Example 1 Granules comprising
• HPC hydroxypropylcellulose
• the granules are produced by granulation of the active compound with low-substituted hydroxypropyl cellulose and an aqueous solution of anhydrous calcium phosphate and HPC in the fluidized bed.
• Example 2 Tablet comprising
• Granules produced as described in Example 1 are admixed with croscarmellose sodium, silicon dioxide and magnesium stearate, the resultant mixture is pressed to give tablets of Example 2.
• the tablets are transferred into HDPE bottles, stored under 30 °C/75%RH for predetermined times and subsequently investigated with respect to active-compound content, dissolution and disintegration. Storage times (in months), dissolution and disintegration times measured in each case are shown in Table 1.
• the granules are produced by granulation of the active compound and an aqueous solution of anhydrous calcium phosphate and PVP-VA in the fluidized bed.
• Granules produced as described in Example 3 are admixed with croscarmellose sodium, silicon dioxide and magnesium stearate, the resultant mixture is pressed to give tablets of Example 4.
• the tablets are transferred into HDPE bottles, stored under 30°C/75%RH for predetermined times and subsequently investigated with respect to active-compound content, dissolution and disintegration. Storage times (in months), dissolution and disintegration times measured in each case are shown in Table 2.
• the granules are produced by granulation of the active compound and an aqueous solution of anhydrous calcium phosphate, PVP-VA and hydroxypropyl cellulose in the fluidized bed.
• HPC hydroxypropyl cellulose
• MMC microcrystalline cellulose
• Vitamin B 12 (as 1% triturate)
• Vitamin B1 and Vitamin B6 are admixed and granulated in an aqueous solution of HPMC in the fluidized bed. Blend of such granules with granules produced as described in Example 1 is blended with Vitamin B12, admixed with MC, croscarmellose sodium, silicon dioxide and magnesium stearate, the resultant mixture is pressed to give tablets.
• the tablets are transferred into HDPE bottles, stored under 30°C/75%RH for predetermined times and subsequently investigated with respect to active-compound content, dissolution and disintegration. Storage times (in months), dissolution and disintegration times measured in each case are shown in Table 3.
• Example 7 Granules comprising
• the granules are produced by granulation of the active compound and an aqueous solution of anhydrous calcium phosphate and PVP-VA in the fluidized bed.
• Example 8 Tablet comprising
• MMC microcrystalline cellulose
• Vitamin B 12 100 mg Vitamin B 12 (as 1% triturate) Vitamin B1 and Vitamin B6 are admixed and granulated in an aqueous solution of HPMC in the fluidized bed. Blend of such granules with granules produced as described in Example 7 is blended with Vitamin B12, admixed with microcrystalline cellulose, croscarmellose sodium, highly dispersed silicon dioxide, and magnesium stearate. The resultant mixture is pressed to give tablets of Example 8.
• Example 8 The tablets of Example 8 are transferred into HDPE bottles, stored under 30°C/75%RH for predetermined times and subsequently investigated with respect to active-compound content, dissolution and disintegration. Storage times (in months), dissolution and disintegration times measured in each case are shown in Table 4.
• Example 1 the granules as prepared in Example 1, 3, 5 and/or 7 are mixed with magnesium stearate as lubricant and transferred and filled into empty hard gelatine capsules.
• granules and tablets are prepared that comprise excipients that are known in the art to stabilize lipoic acid (see, for example, Technical Newsletter/December 2008 from Fuji Chemical Industry relating to Neusilin ® , a synthetic, amorphous form of magnesium aluminometasilicate).
• a blend of active active-compound, stabilizer 1 (silicate) and stabilizer 2 (Neusilin) are compressed by a roller compactor into slugs and broken to provide granules.
• Granules produced as described in Comparative Example 1 are admixed with croscarmellose sodium, silicon dioxide and magnesium stearate, the resultant mixture is pressed to give tablets of Comparative Example 2.
• a blend of active active-compound and stabilizer 1 (silicate) are compressed by a roller compactor into slugs and broken to provide granules.
• Granules produced as described in Comparative Example 3 are admixed with croscarmellose sodium, silicon dioxide and magnesium stearate, the resultant mixture is pressed to give tablets of Comparative Example 4.
• the tablets are transferred into HDPE bottles, stored under 30°C/75%RH for predetermined times and subsequently investigated with respect to active-compound content, dissolution and disintegration. Storage times (in months), dissolution and disintegration times measured in each case are shown in Table 5.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Inorganic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=68966006

Family Applications (1)

Country Status (8)

Family Cites Families (32)

• 2019
  • 2019-11-26 MX MX2021005888A patent/MX2021005888A/es unknown
  • 2019-11-26 CN CN201980077865.9A patent/CN113164396B/zh active Active
  • 2019-11-26 EP EP19824070.7A patent/EP3886814A1/en active Pending
  • 2019-11-26 CA CA3116354A patent/CA3116354A1/en active Pending
  • 2019-11-26 US US16/695,710 patent/US11986460B2/en active Active
  • 2019-11-26 WO PCT/US2019/063135 patent/WO2020112699A1/en unknown
  • 2019-11-26 AU AU2019386979A patent/AU2019386979B2/en active Active
  • 2019-11-26 BR BR112021008602-1A patent/BR112021008602A2/pt unknown

Also Published As

Similar Documents

Legal Events